Description
FDA018-ADC is an experimental medicine being studied in clinical trials for different types of advanced solid tumors, including colorectal cancer. It is being tested to see how safe it is, how the body processes it, and if it shows any early signs of working against the cancer. This is a Phase 1 trial, which means the main goal is to determine the safest dose and understand how patients react to the drug. It is given as an infusion into a vein. The trial design involves starting with low doses and gradually increasing them to find the maximum dose that can be tolerated while managing side effects. The trial also looks at different types of tumors to see if FDA018-ADC might be effective in specific cancer types.
Mechanism of Action
FDA018-ADC is an antibody-drug conjugate (ADC). ADCs are designed to target cancer cells specifically. They combine an antibody, which recognizes and attaches to a protein on the surface of cancer cells, with a chemotherapy drug (payload). The antibody helps deliver the chemotherapy drug directly to the cancer cells, potentially causing less harm to healthy cells compared to traditional chemotherapy. The specific protein targeted by FDA018-ADC and the exact chemotherapy drug it carries are part of the ongoing research.
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.